North Star Asset Management Inc. Boosts Stake in Danaher Co. (NYSE:DHR)

North Star Asset Management Inc. increased its position in shares of Danaher Co. (NYSE:DHR) by 1.0% during the second quarter, HoldingsChannel reports. The institutional investor owned 104,633 shares of the conglomerate’s stock after buying an additional 1,059 shares during the quarter. Danaher accounts for about 1.2% of North Star Asset Management Inc.’s holdings, making the stock its 24th biggest position. North Star Asset Management Inc.’s holdings in Danaher were worth $26,143,000 at the end of the most recent reporting period.

Other institutional investors also recently added to or reduced their stakes in the company. Cary Street Partners Investment Advisory LLC increased its position in Danaher by 20.2% in the 4th quarter. Cary Street Partners Investment Advisory LLC now owns 9,128 shares of the conglomerate’s stock valued at $2,112,000 after acquiring an additional 1,533 shares during the period. Caden Capital Partners LP grew its position in Danaher by 12.4% in the 4th quarter. Caden Capital Partners LP now owns 139,068 shares of the conglomerate’s stock valued at $32,172,000 after buying an additional 15,313 shares during the last quarter. JARISLOWSKY FRASER Ltd increased its stake in Danaher by 10.8% in the 4th quarter. JARISLOWSKY FRASER Ltd now owns 572,858 shares of the conglomerate’s stock valued at $132,524,000 after buying an additional 55,908 shares during the period. HighPoint Advisor Group LLC acquired a new stake in shares of Danaher in the 4th quarter worth $2,614,000. Finally, Norden Group LLC purchased a new stake in shares of Danaher in the first quarter valued at about $4,151,000. Institutional investors and hedge funds own 79.05% of the company’s stock.

Analyst Ratings Changes

DHR has been the topic of a number of analyst reports. Leerink Partners lifted their price objective on Danaher from $275.00 to $280.00 and gave the company an “outperform” rating in a report on Wednesday, July 24th. Robert W. Baird upped their target price on shares of Danaher from $271.00 to $278.00 and gave the stock an “outperform” rating in a research report on Wednesday, July 24th. Stifel Nicolaus lifted their price objective on Danaher from $235.00 to $250.00 and gave the stock a “hold” rating in a report on Wednesday, July 24th. Barclays lifted their price target on Danaher from $270.00 to $285.00 and gave the stock an “equal weight” rating in a research note on Wednesday, July 24th. Finally, Evercore ISI dropped their target price on shares of Danaher from $266.00 to $260.00 and set an “outperform” rating for the company in a report on Tuesday, July 2nd. Seven analysts have rated the stock with a hold rating and eleven have issued a buy rating to the stock. According to MarketBeat.com, Danaher currently has an average rating of “Moderate Buy” and an average price target of $278.94.

Danaher Stock Performance

NYSE DHR opened at $266.19 on Friday. The business’s 50-day simple moving average is $261.30 and its 200-day simple moving average is $255.73. The firm has a market capitalization of $197.16 billion, a P/E ratio of 45.12, a P/E/G ratio of 4.43 and a beta of 0.83. Danaher Co. has a 1-year low of $182.09 and a 1-year high of $281.70. The company has a debt-to-equity ratio of 0.33, a current ratio of 1.43 and a quick ratio of 1.04.

Danaher (NYSE:DHR) last released its quarterly earnings data on Tuesday, July 23rd. The conglomerate reported $1.72 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.57 by $0.15. The company had revenue of $5.74 billion during the quarter, compared to analyst estimates of $5.59 billion. Danaher had a net margin of 16.94% and a return on equity of 11.06%. The business’s quarterly revenue was down 2.9% compared to the same quarter last year. During the same quarter in the prior year, the business earned $2.05 earnings per share. Equities analysts predict that Danaher Co. will post 7.59 EPS for the current year.

Insider Transactions at Danaher

In other Danaher news, SVP Brian W. Ellis sold 9,600 shares of the company’s stock in a transaction that occurred on Thursday, July 25th. The stock was sold at an average price of $275.16, for a total value of $2,641,536.00. Following the completion of the transaction, the senior vice president now owns 20,230 shares in the company, valued at approximately $5,566,486.80. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. In other news, SVP Georgeann Couchara sold 952 shares of the firm’s stock in a transaction dated Monday, August 26th. The stock was sold at an average price of $268.37, for a total transaction of $255,488.24. Following the completion of the sale, the senior vice president now directly owns 4,212 shares in the company, valued at $1,130,374.44. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, SVP Brian W. Ellis sold 9,600 shares of the business’s stock in a transaction dated Thursday, July 25th. The stock was sold at an average price of $275.16, for a total value of $2,641,536.00. Following the completion of the transaction, the senior vice president now owns 20,230 shares in the company, valued at approximately $5,566,486.80. The disclosure for this sale can be found here. Insiders sold 39,659 shares of company stock valued at $11,042,433 over the last quarter. Company insiders own 11.10% of the company’s stock.

About Danaher

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.